Structure and Dynamic Regulation of Abl Kinases*

The c-abl proto-oncogene encodes a unique protein-tyrosine kinase (Abl) distinct from c-Src, c-Fes, and other cytoplasmic tyrosine kinases. In normal cells, Abl plays prominent roles in cellular responses to genotoxic stress as well as in the regulation of the actin cytoskeleton. Abl is also well known in the context of Bcr-Abl, the oncogenic fusion protein characteristic of chronic myelogenous leukemia. Selective inhibitors of Bcr-Abl, of which imatinib is the prototype, have had a tremendous impact on clinical outcomes in chronic myelogenous leukemia and revolutionized the field of targeted cancer therapy. In this minireview, we focus on the structural organization and dynamics of Abl kinases and how these features influence inhibitor sensitivity.

[1]  A. Pendergast,et al.  Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. , 1995, Genes & development.

[2]  G. Superti-Furga,et al.  An intramolecular SH3-domain interaction regulates c-Abl activity , 1998, Nature Genetics.

[3]  T. Smithgall,et al.  Activation of the Src Family Kinase Hck without SH3-Linker Release* , 2005, Journal of Biological Chemistry.

[4]  E. Marzluff,et al.  Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry , 2013, International reviews in physical chemistry.

[5]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[6]  T. Smithgall,et al.  Abl N-terminal cap stabilization of SH3 domain dynamics. , 2008, Biochemistry.

[7]  R. V. van Etten,et al.  Cycling, stressed-out and nervous: cellular functions of c-Abl. , 1999, Trends in cell biology.

[8]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[9]  A. Pendergast.  The Abl family kinases: mechanisms of regulation and signaling. , 2002, Advances in cancer research.

[10]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[11]  T. Smithgall,et al.  Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. , 2008, Journal of molecular biology.

[12]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[13]  J. R. Engen,et al.  Hydrogen exchange mass spectrometry: what is it and what can it tell us? , 2010, Analytical and bioanalytical chemistry.

[14]  S. Goff,et al.  Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. , 1995, Genes & development.

[15]  T. Wales,et al.  Hydrogen exchange mass spectrometry for the analysis of protein dynamics. , 2006, Mass spectrometry reviews.

[16]  R. V. van Etten,et al.  The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. , 1997, Genes & development.

[17]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[18]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[19]  T. Smithgall,et al.  Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner* , 2010, The Journal of Biological Chemistry.

[20]  S. Taylor,et al.  Domain movements in protein kinases. , 1994, Current opinion in structural biology.

[21]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[22]  T. Smithgall,et al.  An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen/deuterium exchange and mass spectrometry , 2006, Protein science : a publication of the Protein Society.

[23]  P. S. Kim,et al.  Structure of the Bcr-Abl oncoprotein oligomerization domain , 2002, Nature Structural Biology.

[24]  Lee Makowski,et al.  Multidomain assembled states of Hck tyrosine kinase in solution , 2010, Proceedings of the National Academy of Sciences.

[25]  John B Wojcik,et al.  Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis , 2011, Cell.

[26]  Y. Tao,et al.  CDK1-mediated Phosphorylation of Abi1 Attenuates Bcr-Abl-induced F-actin Assembly and Tyrosine Phosphorylation of WAVE Complex during Mitosis* , 2011, The Journal of Biological Chemistry.

[27]  Zhongqi Zhang,et al.  Determination of amide hydrogen exchange by mass spectrometry: A new tool for protein structure elucidation , 1993, Protein science : a publication of the Protein Society.

[28]  A. Debnath,et al.  Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1. , 2008, Biochimica et biophysica acta.

[29]  A. Kazlauskas,et al.  c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. , 1999, Genes & development.

[30]  T. Smithgall,et al.  Enhanced SH3/Linker Interaction Overcomes Abl Kinase Activation by Gatekeeper and Myristic Acid Binding Pocket Mutations and Increases Sensitivity to Small Molecule Inhibitors* , 2013, The Journal of Biological Chemistry.

[31]  L. Serrano,et al.  Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions. , 1998, Journal of molecular biology.

[32]  Gennady Verkhivker,et al.  Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations , 2009, PLoS Comput. Biol..

[33]  T. Wales,et al.  Partial unfolding of diverse SH3 domains on a wide timescale. , 2006, Journal of molecular biology.

[34]  Oliver Hantschel,et al.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.

[35]  A. Hvidt,et al.  Hydrogen exchange in proteins. , 1966, Advances in protein chemistry.

[36]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[37]  G. Neubauer,et al.  Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase , 2001, Oncogene.

[38]  D. Monaghan,et al.  Interaction of the N-Methyl-d-Aspartic Acid Receptor NR2D Subunit with the c-Abl Tyrosine Kinase* , 2000, The Journal of Biological Chemistry.

[39]  A. Deisseroth,et al.  Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr–abl positive 32D myeloid leukemia cells , 1998, Oncogene.

[40]  Z. Dai,et al.  MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration , 2008, Leukemia.

[41]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[42]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[43]  G. Superti-Furga,et al.  A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.

[44]  J. Colicelli,et al.  ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity , 2010, Science Signaling.

[45]  R. Dror,et al.  A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.

[46]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[47]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[48]  R. V. van Etten,et al.  Activation of c-Abl Kinase Activity and Transformation by a Chemical Inducer of Dimerization* , 2001, The Journal of Biological Chemistry.

[49]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[50]  John R. Engen,et al.  Analysis of protein conformation and dynamics by hydrogen/deuterium exchange MS. , 2009, Analytical chemistry.

[51]  John Kuriyan,et al.  A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.

[52]  R. V. van Etten,et al.  c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines* , 2000, The Journal of Biological Chemistry.

[53]  G. Superti-Furga,et al.  Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation , 2008, Cell.

[54]  John R. Engen,et al.  Conformational disturbance in Abl kinase upon mutation and deregulation , 2009, Proceedings of the National Academy of Sciences.

[55]  Weidong Yu,et al.  Bcr-Abl induces abnormal cytoskeleton remodeling, β1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway , 2007, Journal of Cell Science.

[56]  J. Minna,et al.  Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1 , 2007, Oncogene.

[57]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.

[58]  J. Wang,et al.  Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential. , 1989, The EMBO journal.

[59]  R. Sakai,et al.  Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases , 1995, Current Biology.

[60]  John R. Engen,et al.  Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase , 2011, PloS one.

[61]  Matthew B. Wilson,et al.  Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity* , 2006, Journal of Biological Chemistry.

[62]  T. Smithgall,et al.  The Abl SH2‐kinase linker naturally adopts a conformation competent for SH3 domain binding , 2007, Protein science : a publication of the Protein Society.

[63]  N. Kallenbach,et al.  Hydrogen exchange and structural dynamics of proteins and nucleic acids , 1983, Quarterly Reviews of Biophysics.

[64]  I. Bahar,et al.  Structure and dynamic regulation of Src-family kinases , 2008, Cellular and Molecular Life Sciences.

[65]  Yoshiaki Washio,et al.  Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. , 2011, Chemistry & biology.

[66]  A. Koleske,et al.  Enhancement of ABL Kinase Catalytic Efficiency by a Direct Binding Regulator Is Independent of Other Regulatory Mechanisms* , 2008, Journal of Biological Chemistry.

[67]  G. Superti-Furga,et al.  Autoinhibition of c-Abl , 2002, Cell.